Notificação de acontecimentos adversos ou reclamações de qualidade
AZ Medical Global

Áreas Terapêuticas
Medicamentos
Recursos
Conectar

Login

Search Medical Information

Para pesquisar informação científica, deverá especificar pelo menos dois termos de pesquisa

Search Medical Information

European Renal Association (ERA) - 61st Congress

May 23 - 26, 2024

FARXIGA (dapagliflozin)
CVRM Emerging Medicine
LOKELMA (sodium zirconium cyclosilicate)

pdf

Kidney-protective Medication and Risk of Adverse Clinical Outcomes in Patients With Chronic Kidney Disease: Preliminary Findings From DISCOVER CKD

pdf

SGLT2i in CKD With High Albuminuria: An Observational Real-world Study

pdf

Impact of CKD Screening in High‑risk Populations and Guideline-directed Therapy on RRT, CV Events, and Mortality in Europe: An IMPACT CKD Analysis

pdf

High Albuminuria in CKD: Prevalence and Characteristics in a Real-world Clinical Setting

pdf

Impact of CKD Screening in High-risk Populations and Guideline-directed Therapy on Cardiovascular Event Occurrence and Costs in Europe: An IMPACT CKD Analysis

pdf

PaCE CKD: Examining Health-related Quality of Life and Financial Burden in Patients With Chronic Kidney Disease: Assessing the Non-clinical Burden of Disease

pdf

PaCE CKD: The Impact of Caregiving on Health-related Quality of Life and Work Productivity in Chronic Kidney Disease: Results From an International Survey

pdf

Information Needs and Emotional Impact When Receiving a Diagnosis of Chronic Kidney Disease: Insights From DISCOVER CKD

pdf

Dosing Low, Winning High: Unlocking the Promise of Endothelin Antagonism for the Treatment of CKD in the Zibotentan/dapagliflozin ZENITH Trials

pdf

Hyperkalaemia-related RAASi Reduction and Estimated Number Needed to Treat to Avoid a First Hospitalisation by Maintaining RAASi

pdf

Maintained Renin-angiotensin-aldosterone System Inhibitor Therapy With Sodium Zirconium Cyclosilicate in Patients With Chronic Kidney Disease

pdf

Duration of Sodium Zirconium Cyclosilicate Treatment and Continuation of RAASi Therapy After a Hyperkalaemia Episode

pdf

Reduced Hospitalisation or Emergency Department Visits With Long- versus Short-term SZC in Patients With History of Hyperkalaemia: GALVANIZE Outcomes

pdf

Renin-angiotensin-aldosterone System Inhibitor (RAASi) Optimisation After Initiating Outpatient SZC Therapy: The GALVANIZE RAASi Real-world Study

Não encontra o que procura?

Contacte-nos

Encontre um Medical Healthcare Partner

Submeter uma questão

A informação incluída neste website é dirigida exclusivamente a profissionais de saúde.

©2024 AstraZeneca. Todos os direitos reservados. PT-19636

Aprovado a 12/2024.

Sobre o AZMedical

AstraZeneca Portugal

Inquérito de Satisfação

Política de Privacidade

Aviso Legal e Termos de Utilização

Notificação de acontecimentos adversos ou reclamações de qualidade

Política de Privacidade

Aviso Legal e Termos de Utilização